Does amiodarone or an implantable cardioverter-defibrillator reduce overall mortality in patients with NYHA class II or III CHF and LVEF of 35 percent or less?
Patients with NYHA class II or III congestive heart failure (CHF) and LVEF of 35 percent or less
Amiodarone or single-lead, shock-only implantable cardioverter-defibrillator (ICD) therapy
Overall mortality (survival)hard clinical
In patients with symptomatic heart failure and reduced ejection fraction, single-lead shock-only ICD therapy reduces mortality by 23%, whereas amiodarone provides no survival benefit.
In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.
Building similarity graph...
Analyzing shared references across papers
Loading...
Gust H. Bardy
Kerry L. Lee
Daniel B. Mark
New England Journal of Medicine
University of Washington
Duke University
Mayo Clinic in Arizona
Building similarity graph...
Analyzing shared references across papers
Loading...
Bardy et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d56c3c75589c71d767cd0d — DOI: https://doi.org/10.1056/nejmoa043399